Najarian J S, Sutherland D E, Simmons R L, Howard R J, Kjellstrand C M, Ramsay R C, Goetz F C, Fryd D S, Sommer B G
Ann Surg. 1979 Oct;190(4):487-500. doi: 10.1097/00000658-197910000-00008.
Between 1968 and 1978, 305 juvenile onset diabetic patients with uremia and 462 nondiabetic uremic patients of similar age received primary renal allografts at the University of Minnesota. Two hundred eight of the diabetic patients are alive and 190 have functioning renal grafts three months to ten years after transplantation. Cumulative patient survival rates at two years for diabetic recipients of kidneys from HLA identical siblings, other related and cadaver donors are 90, 73 and 68%, respectively, the corresponding graft functional survival rates are 90, 67 and 55%. For nondiabetic patients receiving kidneys from the same donor categories the corresponding patient survival rates are 97, 86 and 75%, while the graft functional survival rates are 94, 77 and 64%. The differences in patient and graft survival between diabetic and nondiabetic recipients are statistically significant only for the patients receiving grafts from HLA-nonidentical related donors. For all recipients under the age of 30, there are no statistically significant differences in patient and graft survival. Regardless of the age of the patient or the source of the kidney, the survival of diabetic patients treated with transplantation at our institution is better than the use of chronic hemodialysis, alone. Technical complications do not occur more frequently in diabetic transplant recipients. Cardiovascular disease is responsible for most of the late deaths in these diabetic patients. Amputations of digits or extremities have been required in 15% of the diabetic patients. On the positive side, the vision of 88% of these recipients remained stable or had improved visual acuity, and 82% of the diabetic patients were actively rehabilitated after transplantation. Kidney transplantation is the treatment of choice for end-stage renal failure in diabetic patients, just as it is for most uremic patients.
1968年至1978年间,明尼苏达大学为305名患有尿毒症的青少年糖尿病患者和462名年龄相仿的非糖尿病尿毒症患者进行了初次肾移植。208名糖尿病患者存活,其中190名患者在移植后3个月至10年拥有功能正常的肾移植。来自HLA同型同胞、其他亲属和尸体供者肾脏的糖尿病受者在移植后两年的累积患者生存率分别为90%、73%和68%,相应的移植肾功能生存率分别为90%、67%和55%。对于接受相同供者类型肾脏的非糖尿病患者,相应的患者生存率分别为97%、86%和75%,而移植肾功能生存率分别为94%、77%和64%。糖尿病和非糖尿病受者在患者和移植肾存活方面的差异仅在接受HLA非同型亲属供者移植的患者中具有统计学意义。对于所有30岁以下的受者,患者和移植肾存活方面没有统计学上的显著差异。无论患者年龄或肾脏来源如何,在我们机构接受移植治疗的糖尿病患者的存活率都高于单纯使用慢性血液透析。糖尿病移植受者发生技术并发症的频率并不更高。心血管疾病是这些糖尿病患者大多数晚期死亡的原因。15%的糖尿病患者需要进行手指或肢体截肢。从积极的方面来看,这些受者中有88%的视力保持稳定或视力提高,82%的糖尿病患者在移植后积极康复。肾移植是糖尿病患者终末期肾衰竭的首选治疗方法,就像对大多数尿毒症患者一样。